Local view for "http://purl.org/linkedpolitics/eu/plenary/2008-09-02-Speech-2-037"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2008-09-02"^^xsd:date2
dcterms:Is Part Of	lp_eu:Social package (First part) (debate)2
dcterms:Language	"da"^^xsd:language2
lpv:document identification number	"en.20080902.4.2-037"2
lpv:hasSubsequent	lp_eu:2008-09-02-Speech-2-0392
lpv:speaker	lp:Hanne Dahl2
lpv:spokenAs	member_of_the_bureau; IND/DEM (2008-05-09--2008-10-21)3 unknown; JuniBevægelsen - Mod Unionen (2008-05-09--2009-07-13)3 member; AFCO (2008-05-09--2009-07-13)3 substitute; CONT (2008-05-09--2009-07-13)3 substitute; ENVI (2008-05-09--2009-07-13)3 substitute; IMCO (2008-05-09--2009-07-13)3 vice-chair; Delegation for relations with Switzerland, Iceland and Norway and to the European Economic Area (EEA) Joint Parliamentary Committee (2008-06-03--2009-07-13)3
lpv:translated text	"Mr President, I would like to use my speaking time today to focus on the health policy agenda. The current proposal for the Directive on patients’ rights in cross-border healthcare has been improved significantly in relation to the original proposal. However, unfortunately no change has been made in connection with the fundamental grounds for all matters that fall under the internal market. Consideration for the free market always wins over consideration for the people. It goes without saying that we all want to be able to receive the best treatment as quickly as possible if we become seriously ill. Unfortunately, the directive does not in any way ensure that this will be the case. It ensures that the wealthiest patients from the wealthiest countries in the EU will receive the best possible treatment. This means that there is a great risk of patients becoming divided into a group A and a group B. The patients with the most resources will have the opportunity to seek the best treatment in other countries, whereas those without funds or power will not have this opportunity. The directive secures an entitlement to treatment in another country at the cost of that same treatment in the patient’s home country. This also creates the risk of having A and B countries. The cost of the same treatment will naturally vary from country to country. The current directive allows market conditions to determine the outcome, but this is a high-risk approach. When the market reacts, the losers will always be those who cannot cope under the prevailing market conditions."@en1
lpv:videoURI	<go to Events_and_structure europarl>2

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph